




The relative strengths and weaknesses of Syros Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Syros Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 131% points. The greatest weakness of Syros Pharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 341%, being 97% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	85,508
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,567
Liabilities, Non-Current	0
Other Assets	965
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	537
Other Revenues	0
Property and Equipment	4,850
Research and Development	37,817
Selling, General and Administrative Expense	10,463

Output Variable	Value in 1000 USD
Assets	91,323
Liabilities	9,567
Expenses	48,280
Revenues	0
Stockholders Equity	81,756
Net Income	-47,743
Comprehensive Net Income	-47,743
BaseVar	74,854
ECR before Limited Liability	259%
Economic Capital Ratio	341%